Financial Personal
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
TORONTO and HAIFA, Israel , Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traum
About NurExone Biologic Inc. Read More
Related
Share this page
Guest Posts by Easy Branches